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Abstract
Background: Despite limited evidence of effectiveness, withdrawal (discontinuation or dose reduction) of high risk
medications known as “fall-risk increasing drugs” (FRIDs) is typically conducted as a fall prevention strategy based
on presumptive benefit. Our objective is to determine the efficacy of fall-risk increasing drugs (FRIDs) withdrawal on
the prevention of falls and fall-related complications.
Methods/design: We will search for all published and unpublished randomized controlled trials evaluating the
effect of FRID withdrawal compared to usual care on the rate of falls, incidence of falls, fall-related injuries,
fall-related fractures, fall-related hospitalizations, or adverse effects related to the intervention in adults aged
65 years or older. Electronic database searches will be conducted in MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trials (CENTRAL), and CINAHL. A grey literature search will be conducted including clinical
trial registries and conference proceedings and abstracts. Two reviewers will independently perform in duplicate
citation screening, full-text review, data abstraction, and risk of bias assessment. Conflicts will be resolved
through team discussion or by a third reviewer if no consensus can be reached. The Grades of Recommendation,
Assessment, Development and Evaluation (GRADE) criteria will be used to independently rate overall confidence in
effect estimates for each outcome. Results will be synthesized descriptively, and a random effects meta-analysis will be
conducted for each outcome if studies are deemed similar methodologically, clinically, and statistically.
Discussion: We will attempt to determine whether a FRID withdrawal strategy alone is effective at preventing
falls in older adults. Our results will be used to optimize and focus fall prevention strategies and initiatives
internationally with a goal of improving the health of older adults.
Systematic review registration: PROSPERO CRD42016040203
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Background
Falls and fall-related injuries among older adults are sig-
nificant public health concerns due to their high inci-
dence and associated morbidity and mortality. Every
year, 1 in 3 seniors aged 65 years or older fall and 10%
of these falls cause serious injury and/or hospitalization
[1]. Current fall prevention clinical practice guidelines
focus on multi-component assessment and intervention
strategies [2]. However, it is unclear which parts of the
multi-component strategy are effective and how large
the treatment effect is for individual interventions.
Despite limited evidence of effectiveness, withdrawal
(discontinuation or dose reduction) of high risk medi-
cations known as “fall-risk increasing drugs” (FRIDs) is
typically included in these multi-component strategies.
The justification for FRID withdrawal is based on
retrospective observational data showing that the use
of certain medications is a significant risk factor for
falls. These medications include anti-hypertensives
(e.g., diuretics, beta-blockers), anti-arrhythmics, anti-
cholinergics, anti-histamines, sedatives and hypnotics
(e.g., benzodiazepines), neuroleptics, antidepressants,
narcotics, and nonsteroidal anti-inflammatory drugs
(NSAIDs) [3–5]. This evidence, however, is based pri-
marily on observational data with minimal adjustment
for confounders, dosage, or duration of therapy. It is
therefore unclear whether the associated increase in
falls is truly related to the use of these drugs or the
underlying conditions that the drugs are treating.
In order to justify the current common practice of
FRID withdrawal, the presumption of its effectiveness as
a falls prevention strategy needs to be confirmed. A pro-
spective cohort study showed that FRID withdrawal was
associated with a reduction in falls (HR 0.48, 95% CI
0.23–0.99) [6], but this needs to be replicated with high
quality randomized controlled trials (RCT) evidence.
There have been a number of systematic reviews that
have assessed the effectiveness of all available interven-
tions designed to prevent falls [7–10]. However, only
two of these systematic reviews were designed specific-
ally for medication-related interventions for falls pre-
vention, and their methodological quality is relatively
low (AMSTAR scores of 3) [1, 11]. To date, there is no
systematic review that has specifically examined the
effectiveness of FRID withdrawal on falls prevention.
The most recent systematic review with strong meth-
odological rigour is a 2012 Cochrane review of fall pre-
vention interventions in the community [7]. It identified
five trials investigating the effect of medication with-
drawal. Gradual withdrawal of psychotropic medications
in one RCT reduced the rate of falls (RaR 0.34, 95% CI
0.16–0.73), but not the risk of falling [12]. Three of four
RCTs of medication review and modification did not re-
duce falling rate or risk.
Our specific systematic review research question is “In
older adults age ≥65 years, does the withdrawal of fall-
risk increasing drugs (FRIDs) decrease the risk of falls
compared to usual care and continuation of these
drugs?”. The aim of this systematic review is to assess
the effectiveness of FRID withdrawal as an individual
intervention to prevent falls across all care settings and
to clarify the evidence base supporting its current prac-
tice and presumptive effectiveness. It will update previ-
ous systematic reviews by incorporating new recent data
from the largest RCT of FRID withdrawal to date [13],
focus future medication-related fall prevention strat-
egies, and identify current gaps in evidence.
Methods/design
This protocol was developed using the Cochrane
Handbook for Systematic Reviews of Interventions as
methodological framework and reported in accordance
with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Protocols (PRISMA-P)
guidelines [14, 15]. A completed PRISMA-P recom-
mendation checklist is included as an additional file
(see Additional file 1). Our protocol has been regis-
tered in the PROSPERO database (CRD42016040203).
Eligibility criteria
Types of studies
All published and unpublished RCTs, cluster RCTs, and
quasi-RCTs (e.g., allocation by alternation or date of
birth) comparing a FRID withdrawal intervention (dis-
continuation or dose reduction) to usual care (i.e., no
withdrawal) will be included.
Types of participants
We will include all studies focused on older adults aged
65 years or older from all settings (e.g., community,
acute care, long-term care, and rehabilitation).
Types of interventions and comparators
We will include all interventions that withdraw FRIDs
(single or multiple medications) with the intent of re-
ducing the risk of future falls compared to usual care
(i.e., no FRID withdrawal and/or no change in usual
activities). The intervention may be accompanied by a
preceding medication review for FRID withdrawal ap-
propriateness. There will be no restrictions placed on
the professional background of the individual conduct-
ing FRID withdrawal and/or medication review. Studies
involving FRID withdrawal as part of a more complex
multi-component intervention will be excluded.
Types of outcome measures
The primary outcomes of this review are the (1) rate of
falls and (2) incidence of falls (i.e., number of fallers).
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Secondary outcomes will include the incidence of (1)
fall-related fractures, (2) fall-related injuries, (3) fall-
related hospitalization, (4) adverse effects related to the
withdrawal intervention (e.g., disease relapse, symptom-
atic withdrawal).
Search methods
Comprehensive search strategies will be developed in
consultation with an experienced librarian. Electronic
database searches will be conducted in MEDLINE,
EMBASE, Cochrane Central Register of Controlled Tri-
als (CENTRAL), and Cumulative Index to Nursing and
Allied Health Literature (CINAHL) using a combination
of medical subject headings, controlled and free-text
terms with various synonyms for the intervention. The
Ovid Medline search strategy is shown as an example in
an additional file (see Additional file 2). A similar search
strategy will be used in the other databases. No restric-
tions will be placed on language, year of publication, or
time (i.e., studies of all durations will be included).
The search will be repeated prior to final manuscript
submission. The reference lists of all included studies,
relevant systematic reviews, and guidelines will be
manually hand searched for additional eligible studies.
We will perform a grey literature search through the fol-
lowing: (1) trial registries (e.g., ClinicalTrials.gov, World
Health Organization Clinical Trials Search Portal) and
(2) conference proceedings and abstracts in for the most
recent meetings (2012 to 2015) of the Canadian Geriat-
rics Society, American Geriatrics Society, and European
Union Geriatric Medicine Society. We will contact pri-
mary authors to determine whether results are available
and include these trials in the systematic review if
appropriate.
Study selection
Two independent reviewers will screen available titles
and abstracts to assess for possible inclusion and full-
text review using the Covidence online software
(https://www.covidence.org). From the full text, two
reviewers will independently assess potentially eligible
trials in duplicate for inclusion. Studies will be in-
cluded when both reviewers agree about their inclu-
sion. Any disagreement will be resolved through
discussion or by a third reviewer if no consensus can
be reached. If needed, authors will be contacted for
any additional details required to clarify study eligibil-
ity. Reason(s) for exclusion of any studies will be docu-
mented. Eligible study citations will be saved into the
Mendeley reference manager library.
In an initial pilot run of study selection of a random
sample of 50 citations, the kappa statistic will be mea-
sured to determine inter-rater agreement on study selec-
tion and reveal any problems with the protocol requiring
modification. Full screening will only begin when there
is >95% agreement.
Data extraction
Study data will be extracted independently in duplicate
by two reviewers using a data extraction form devel-
oped in Microsoft Word. The following information
will be extracted: study characteristics, patient charac-
teristics, intervention characteristics, and outcome re-
sults from each time period reported in the study and/
or the longest duration of follow-up. Any disagreement
will be resolved through discussion or by a third re-
viewer if no consensus can be reached. Study authors
will be consulted for additional or missing information
where appropriate. All reviewers will pilot test the data
extraction form prior to the full review to identify any
problems with the form requiring modification.
Assessment of risk of bias
All included studies will be assessed in duplicate by two
independent reviewers for risk of bias using a modified
version of the Cochrane Risk of Bias tool based on ran-
dom sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants,
personnel and outcome assessors (performance and de-
tection bias), completeness of follow-up (attrition bias),
selective outcome reporting, and other biases (e.g., recall
bias due to unreliable method of falls ascertainment)
[16]. Each criterion will be assigned a score of definitely
low risk, probably low risk, probably high risk, or defin-
itely high risk [17]. Definitely and probably scores will be
collapsed to low risk and high risk, respectively, to allow
for low vs. high risk sensitivity analysis. Any disagree-
ment will be resolved through discussion or by a third
reviewer if no consensus can be reached.
Selective outcome reporting bias will be examined by
making efforts to access study protocols (e.g., obtain
published protocols, check trial databases, or request
from study author). Outcomes reported in the protocol
will be compared with those reported in the paper. Fur-
thermore, outcomes reported in the methods will be
compared with those reported in the results sections of
the study papers.
If there are ten or more included studies in the meta-
analysis for one of the outcomes, a funnel plot will be
constructed to visually inspect for potential publication
bias.
Measurement of treatment effects
The treatment effect for rate of falls will be reported as a
rate ratio (RaR) and 95% confidence interval (CI) be-
tween the intervention and comparator groups. The rate
of falls will be defined as the total number of falls per
unit of person time that falls were monitored (e.g., falls
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per person year). If both adjusted and unadjusted rate
ratios are reported, the unadjusted estimate will be used
unless adjustment was conducted to account for cluster
design effect. If a rate ratio is not reported, the rate ratio
and 95% CI will be calculated using raw data (if avail-
able) of the total number of falls, and the actual total
length of time falls were monitored (person years).
The treatment effect for the dichotomous incidence
outcomes (i.e., incidences of falls, fall-related fracture,
fall-related injury, fall-related hospitalization, and ad-
verse effects related to the withdrawal intervention) will
be reported as a risk ratio (RR) and 95% CI. If both
adjusted and unadjusted risk ratios are reported, the
unadjusted estimate will be used unless adjustment was
conducted to account for cluster design effect. If a risk
ratio is not reported or an odds ratio is reported, the
risk ratio and 95% CI will be calculated using raw data
(if available).
For any included cluster RCTs where treatment effects
are reported at the cluster rather than the individual
level, adjustments for the cluster design effect using
intra-cluster coefficient (ICC) estimates and average
cluster size will be conducted (if available).
Data synthesis and summary of results
A GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) evidence profile (EP) and
summary of findings (SoF) table will be created for each
outcome [18]. Prior to conducting meta-analysis, we will
assess for statistical, clinical, and methodological hetero-
geneity. Statistical analysis will be conducted using Rev-
Man 5.1 and SPSS Statistics v20. If deemed feasible and
appropriate, meta-analysis will be conducted. Since vari-
ations in methodological, participant, and medication
characteristics are expected between studies, a random
effects model will be used. Data will be pooled to esti-
mate the treatment effect at various time intervals de-
pending on the follow-up duration of the included
studies (i.e., <3 months, 3–6 months, 6–12 months,
≥12 months). Pooled data will be presented using forest
plots and qualitative descriptions. For studies where
meta-analysis is not appropriate, results will be described
qualitatively, and their significance to the rest of the
body of evidence will be discussed.
Assessment of heterogeneity
Heterogeneity within a pooled group of trials will be
assessed using a combination of visual inspection of
the forest plot and consideration of statistical tests for
heterogeneity. The presence of statistically significant
heterogeneity will be measured by calculating the Chi
square statistic, and the degree of heterogeneity will
be quantified by calculating the I2 statistic. The I2 will
be interpreted using the thresholds described by the
Cochrane Collaboration [14]. A two-tailed test with p
value < 0.10 will be considered to be significant for all
analyses.
If substantial statistical heterogeneity is found (e.g.,
I2 ≥ 50%) or substantial clinical or methodology hetero-
geneity is noted (based on team’s expertise), sources of
heterogeneity will be explored via a priori subgroup
analyses. We are proposing five a priori hypotheses to
explain possible heterogeneity between studies (see
Additional file 3). These include differences in baseline
propensity for falls as influenced by (1) a history of re-
current falls (e.g., known faller or not) or (2) place of
residence or care (e.g., community, long-term care); dif-
ferences in the intervention as influenced by (3) specific
medication class(es) chosen for withdrawal and (4) pre-
ceding medication review by clinician for FRID with-
drawal appropriateness; as well as differences in
methodology based on (5) definitions used for “falls”
(e.g., observed vs. self-reported).
Management of missing data
Any missing outcome data will be requested from au-
thors. If missing data still exists, a senior methodologist
will be consulted to advise whether it is appropriate to
impute missing data with replacement values (e.g., last
observation carried forward). Otherwise, analysis will be
conducted on the final available data, and the potential
impact of missing data on the review findings will be ad-
dressed in the Discussion section of the final report.
Sensitivity analyses
Sensitivity analyses will be conducted to compare results
with (1) low vs. high risk of bias studies and (2)
intention-to-treat vs. per-protocol analysis.
Assessment of confidence in estimates of effects
Two independent reviewers will assess in duplicate the
confidence in the estimates of the effects of the interven-
tion (i.e., quality of evidence) for each reported outcome
using the GRADE approach [18]. Confidence will be
rated as high, moderate, low, or very low for each of the
following criteria: risk of bias, inconsistency, indirect-
ness, imprecision, and publication bias. Any disagree-
ment will be resolved through discussion or by a third
reviewer if no consensus can be reached.
Discussion
Understanding and advancing our knowledge of the
most effective fall prevention strategies is crucial to im-
proving the health of older adults. Falls and their asso-
ciated complications can cause significant morbidity,
mortality and burden on patients, their families, and
society. In Canada, for example, falls are the leading
cause of injury and injury-related hospitalizations for
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seniors in Canada with annual healthcare costs exceed-
ing $2 billion.
Medication optimization and FRID withdrawal has
commonly been included as part of multi-component
fall prevention interventions based on lower quality,
retrospective evidence of association. Given the signifi-
cant time and resources often required to successfully
deprescribe patients from many of these medications, it
is imperative to confirm its presumptive effectiveness as
a falls prevention strategy.
To our knowledge, this will be the first systematic re-
view evaluating the efficacy and safety of FRID with-
drawal on the prevention of falls and fall-related
complications in older adults. Our review will use high
quality, rigorous systematic review methodology including
an independent duplicate risk of bias assessment and an
assessment of the quality of evidence using the GRADE
approach. The results of the systematic will be reported in
accordance with the PRISMA statement [19].
We will ensure that our results will be used to inform
the activities of a wide variety of knowledge users and
stakeholders including patients, clinicians, administra-
tors, and policy-makers. Our findings will be dissemi-
nated through a variety of end-of-grant knowledge
translation strategies including conference presentations,
peer-reviewed publications, and dissemination to rele-
vant stakeholder groups with an interest in the manage-
ment and prevention of falls.
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